In this study, we investigated the potential of SMYD2 to serve as a prognostic marker for ccRCC by determining the SMYD2 expression in ccRCC samples and correlating its expression with various clinicopathologic factors. This evidence concerns the gene SMYD2 and nonpapillary renal cell carcinoma.